1-866-598-7166

A Study of BMS-986488 as Monotherapy and Combination Therapy in Patients with Advanced Malignant Tumors

Trial ID: NCT06764771
Kidney Cancer Type: Clear cell only


Background:

BMS-986488 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies.

Nivolumab (Opdivo®) is an immunotherapy that works by boosting the body’s immune system to recognize and attack cancer cells.

Since this drug is still in the clinical trial phase, it has the placeholder name BMS-986488 rather than a commercial trade name.


The Trial:

This study will investigate safety and effectiveness as a anti-cancer drug of BMS-986488, alone, or in combination with other drugs such as Adagrasib, Cetuximab, and Nivolumab in patients with advanced malignant tumors.

Kidney cancer participants will be sequentially assigned to one of the below treatment regimes:

  • BMS-986488 alone
  • BMS-986488 + Nivolumab

The trial is not “blind”, so both you and your doctor will know which therapy you are receiving. 


Basic Eligibility:

  • Clear cell renal cell carcinoma only (ccRCC)
  • Cancer is locally advanced, metastatic, or cannot be removed by surgery

 

Additional eligibility criteria will apply. Please speak to your doctor.

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreBC Cancer Principal InvestigatorDr. Christian Kollmannsberger LocationVancouver, BC Trial StatusRecruiting
Hospital / Cancer CentreCentre intégré de cancérologie du CHU de Québec Université Laval Principal InvestigatorDr. Antoine Morin Coulombe LocationQuebec city, QC Trial StatusRecruiting
Hospital / Cancer CentreCentre Hospitalier de l'Université de Montréal (CRCHUM) Principal InvestigatorNot Given LocationMontreal, QC Trial StatusNot Yet Recruiting
Kidney Cancer Canada